| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
Tridecanoic acid-d2 is a substrate for medium-chain acyl-CoA synthetases and mitochondrial β-oxidation, and it can be elongated to C15:0 and C17:0 fatty acids and incorporated into triglycerides and phospholipids; the parent fatty acid inhibits E. coli persistence and biofilm formation through a mechanism that is not linked to a single receptor but may involve membrane perturbation and disruption of bacterial adhesion.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
In vitro, tridecanoic acid-d2 is taken up by cultured cells and incorporated into complex lipids; it inhibits E. coli persistence and biofilm formation, and the deuterated form serves as an internal standard for LC-MS/MS quantification of C13:0 in lipid extracts, with co-elution and identical ionization behavior ensuring accurate quantification. |
| ln Vivo |
In vivo, orally administered tridecanoic acid-d2 is absorbed, distributed to liver, adipose tissue, and skeletal muscle, and esterified into triglycerides and phospholipids or oxidized via β-oxidation; tracer enrichment in plasma and tissue lipid pools reveals elongation and incorporation dynamics, and the d2 label allows discrimination from dietary and endogenous C13:0.
|
| Enzyme Assay |
Noncellular assays quantify tridecanoic acid-d2 and its elongation/oxidation products by GC-MS or LC-MS/MS after lipid extraction and derivatization; β-oxidation flux is measured in isolated mitochondria or permeabilized cells using deuterated tridecanoyl-carnitine and electron acceptors, and antibiofilm activity is assessed by crystal violet staining and persistence assays in E. coli cultures.
|
| Cell Assay |
Cellular assays incubate HepG2, C2C12, or 3T3-L1 cells with tridecanoic acid-d2–bovine serum albumin complexes, followed by lipid extraction and mass spectrometric quantification of deuterated triglycerides, phospholipids, and elongated C15:0/C17:0 products; fatty acid uptake is measured by fluorescence-activated cell sorting or scintillation counting.
|
| Animal Protocol |
Animal protocols administer tridecanoic acid-d2 by oral gavage or incorporation into semisynthetic diets in mice or rats; plasma, liver, adipose tissue, and skeletal muscle are collected over time for mass spectrometric quantification of the tracer and its elongation/oxidation products, and lipidomics are used to relate C13:0 flux to tissue lipid storage and oxidation.
|
| References |
| Molecular Formula |
C13H24D2O2
|
|---|---|
| Molecular Weight |
216.36
|
| Exact Mass |
216.206
|
| CAS # |
64118-44-1
|
| Related CAS # |
Tridecanoic acid;638-53-9
|
| PubChem CID |
71309231
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
236ºC/100 mmHg
|
| Melting Point |
41-42ºC(lit.)
|
| Flash Point |
113ºC
|
| LogP |
4.382
|
| tPSA |
37.3
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
15
|
| Complexity |
144
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[2H]C([2H])(CCCCCCCCCCC)C(=O)O
|
| InChi Key |
SZHOJFHSIKHZHA-XUWBISKJSA-N
|
| InChi Code |
InChI=1S/C13H26O2/c1-2-3-4-5-6-7-8-9-10-11-12-13(14)15/h2-12H2,1H3,(H,14,15)/i12D2
|
| Chemical Name |
2,2-dideuteriotridecanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~462.2 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (11.55 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (11.55 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (11.55 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.6219 mL | 23.1096 mL | 46.2193 mL | |
| 5 mM | 0.9244 mL | 4.6219 mL | 9.2439 mL | |
| 10 mM | 0.4622 mL | 2.3110 mL | 4.6219 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.